|Bid||6.21 x 2900|
|Ask||6.23 x 800|
|Day's Range||6.05 - 6.63|
|52 Week Range||1.75 - 7.25|
|Beta (5Y Monthly)||2.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets.It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.Five Prime Therapeutics shares were trading up 20.53% at $5.30 on Monday. The stock has a 52-week high of $6.54 and a 52-week low of $1.75.Latest Ratings for FPRX DateFirmActionFromTo Jun 2020WedbushUpgradesNeutralOutperform Feb 2020JP MorganDowngradesNeutralUnderweight Feb 2020WedbushDowngradesOutperformNeutral View More Analyst Ratings for FPRX View the Latest Analyst RatingsSee more from Benzinga * Why Gap's Stock Is Trading Higher Today * Cruise Stocks Fall After Halting Trips From US Ports * Apple Will Close 11 Stores As COVID-19 Cases Flare Up In Some States(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Five Prime Therapeutics (FPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) just released its first-quarter report and things are looking bullish...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shareholders will doubtless be very grateful to see the share price up 33...
Lewis "Rusty" Williams founded Five Prime Therapeutics nearly 20 years ago. Now he, the co-inventor of the cancer drug Opdivo and two other Five Prime executives are deep into a new startup.
New York-born, Bay Area-raised Brian Wong is doing the hard work of broadening a drug pipeline with what he describes as a “Brooklyn toughness."
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -8.42% and -31.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
This cancer-fighting biotech was one of the early companies to commit to The Cove at Oyster Point; now it may sublease some or all of its space.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ...
Biotech stocks came under selling pressure in the week ended Sept. 27 amid clinical data readouts and a handful of FDA decisions. AIM ImmunoTech Inc (NYSE: AIM ) was the worst decliner of the week, as ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 19.) 10X Genomics Inc (NASDAQ: TXG ) (listed its ...
If you want to know who really controls Five Prime Therapeutics, Inc. (NASDAQ:FPRX), then you'll have to look at the...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -15.12% and -39.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?